Anti-doping testing raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Nine mobile detachments (Panjin, Liaoning; Shenyang, Liaoning; Bayisingtu, Inner Mongolia; Tianjin; Dingzhou, Hebei; Baoding, Hebei; Jinzhong, Shanxi; Zhengzhou, Henan; Pingliang, Gansu); Three Special Operations detachments (Beijing; Tianjin; Shijiazhuang); Two Transportation detachments (Beijing and Xi’an, Shaanxi); One Engineering/Chemical Defence detachment (Huludao, Liaoning); One Helicopter detachment with 3 Groups
The three general categories of preparation of PRP based on leukocyte and fibrin content are leukocyte-rich PRP, leukocyte reduced PRP, and leukocyte platelet-rich fibrin. The efficacy of certain growth factors in healing various injuries and the concentrations of these growth factors found within PRP are the theoretical basis for the use of PRP in tissue repair. Though not required for the process, platelets can be activated by the addition of thrombin or calcium chloride, which induce the release of the factors from alpha granules. The addition of thrombin or calcium chloride is not required as natural thrombin activates the cells upon injection. The growth factors and other cytokines present in PRP include:
=== Phylloxera === There have been several theories proposed for why the phylloxera was ignored as the possible cause of the disease that resulted in the failure of so many vineyards, most of which involve the feeding behaviour of the insect, and the way it attacks the roots. The proboscis of the grape phylloxera has both a venom canal from which it injects its deadly venom and a feeding tube through which it takes in vine sap and nutrients. As the toxin from the venom corrodes the root structure of a vine, the sap pressure falls and, as a result, the Phylloxera quickly withdraws its feeding tube and searches for another source of food. Thus, anyone digging up a diseased and dying vine will not find Phylloxera clinging to the roots of the plant.
Sources: en.wikipedia.org
McGuinn's concept was jettisoned in favor of a country project, which included Parsons' songs "One Hundred Years from Now" and "Hickory Wind", and songs by Bob Dylan, Woody Guthrie and Merle Haggard. Recording sessions for Sweetheart of the Rodeo commenced at Columbia Records' recording studios in the Music Row area of Nashville on March 9, 1968. Mid-way through, the sessions moved to Columbia Studios, Hollywood and were completed on May 27, 1968. However, Parsons was still under contract to LHI Records and Hazlewood threatened legal action over Parsons' appearance on the album. As a result, McGuinn replaced three of Parsons' lead vocals with his own; in 1973, in an interview with Cameron Crowe, Parsons said that McGuinn "erased it and did the vocals himself and fucked it up." Parsons remained as lead vocalist on the songs "You're Still on My Mind", "Life in Prison", and "Hickory Wind". While in England with the Byrds in the summer of 1968, Parsons left the band over a planned concert tour of South Africa and his opposition to apartheid. During this period Parsons became acquainted with Mick Jagger and Keith Richards of The Rolling Stones. After leaving the band, Parsons stayed at Richards' house and the pair developed a close friendship, with Parsons reintroducing the guitarist to country music.
=== Classification criteria === In 2010, the 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria were introduced. The new criteria are not diagnostic criteria, but are classification criteria to identify disease with a high likelihood of developing a chronic form. However a score of 6 or greater unequivocally classifies a person with a diagnosis of rheumatoid arthritis. These new classification criteria overruled the "old" ACR criteria of 1987 and are adapted for early RA diagnosis. The "new" classification criteria, jointly published by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), establish a point value between 0 and 10. Four areas are covered in the diagnosis:
== Melamine on metal surfaces == It is reported that melamine molecules adsorbed on gold or silver surface tend to arrange into honeycomb or closed-packed structures. Such a self-assembly occurs due to the inter-molecular hydrogen bond interaction. This ordering was further investigated using classical Monte Carlo and DFT methods.
Sources: en.wikipedia.org
=== Molecular Characterization === Dynamic light scattering (DLS) Matrix-assisted laser desorption/ionization (MALDI) spectrocosopy Nuclear magnetic resonance (NMR) spectroscopy Size exclusion chromatography (SEC)
Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, chronic neuropathic pain, fibromyalgia, and menopausal symptoms. Off-label uses include treatments for attention deficit hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters. Since norepinephrine pathways play a role in pain modulation, SNRIs are also widely used for chronic pain conditions such as neuropathic pain and fibromyalgia. The human serotonin transporter (SERT) and norepinephrine transporter (NET) are membrane transport proteins that are responsible for the reuptake of serotonin and norepinephrine from the synaptic cleft back into the presynaptic nerve terminal. Dual inhibition of serotonin and norepinephrine reuptake can offer advantages over other antidepressant drugs by treating a wider range of symptoms. They can be especially useful in concomitant chronic or neuropathic pain. SNRIs, along with SSRIs and NRIs, are second-generation antidepressants.
Because of the practical and, in particular, the financial scale of the program needed, the NCI decided to seek association with a pharmaceutical company, and in August 1989, it published a Cooperative Research and Development Agreement (CRADA) offering its current stock and supply from current bark stocks, and proprietary access to the data so far collected, to a company willing to commit to providing the funds to collect further raw material, isolate taxol, and fund a large proportion of clinical trials. In the words of Goodman and Welsh, authors of a substantial scholarly book on taxol, "The NCI was thinking, not of collaboration, ... but of a hand-over of taxol (and its problems)". Although the offer was widely advertised, only four companies responded to the CRADA, including the American firm Bristol-Myers Squibb (BMS), which was selected as the partner in December 1989. The choice of BMS later became controversial and was the subject of Congressional hearings in 1991 and 1992. While it seems clear the NCI had little choice but to seek a commercial partner, there was also controversy about the terms of the deal, eventually leading to a report by the General Accounting Office in 2003, which concluded the NIH had failed to ensure value for money. In related CRADAs with the USDA and Department of the Interior, Bristol-Myers Squibb was given exclusive first refusal on all Federal supplies of Taxus brevifolia. This exclusive contract lead to some criticism for giving BMS a "cancer monopoly".
=== Music === The majority of Library of Ruina's soundtracks were created by two music studios, South Korean game sound studio Studio EIM and Japanese indie band Mili. Studio EIM composed music for the main menu, receptions, Abnormality suppressions, and floor realizations. In a typical reception, the floor's background music changes corresponding to its emotion level. For Library of Ruina, Mili made a mini album, To Kill A Living Book, with seven out of the eight songs being tailored to specific characters. A small number of other tracks were borrowed from the prequel installment, Lobotomy Corporation.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.